Novo Nordisk presents positive long-term results for Saxenda
June 3, 2016Medical Communications, Research and Development Novo Nordisk, cardiometabolic risk factors, liraglutide, saxenda, weight loss
Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the …
Shire completes Baxalta takeover
June 3, 2016Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales
UK drugmaker Shire (LSE: SHP) on Friday announced the completion of merger with rare disease specialist Baxalta (NYSE: BXLT). The …
Eisai partners with Novartis in renal cell carcinoma collaboration
June 3, 2016Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate
Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …
Bayer, Orion to start Phase III trials for prostate cancer drug
June 3, 2016Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research
German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …
New FDA expanded access guidelines spell trouble for Sarepta
June 2, 2016Medical Communications, Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, Eteplirsen, FDA, compassionate grounds, sarepta
New guidelines intended to streamline the process of expanded access to medicines by the US Food and Drug Administration (FDA) …
Biogen Alzheimer’s treatment accepted into EMA’s PRIME scheme
June 2, 2016Research and Development, Sales and Marketing Alzheimer's, Biogen, EMA, PRIME, accelerated approval
Biogen (NASDAQ: BIIB) has announced that the European Medicines Agency (EMA) has accepted its investigational treatment for Alzheimer’s disease, aducanumab, …
Global oncology market to reach $150 billion by 2020, says IMS Health
June 2, 2016Research and Development IMS Health, annual global growth, cancer drugs, oncology
Global sales of oncology drugs rose to $107 billion in 2015, according to a new IMS Health report, with growth …
AstraZeneca licenses gout drug Zurampic to Grünenthal in Europe and Latin America
June 2, 2016Business Services, Manufacturing and Production, Sales and Marketing AstraZeneca, Grunenthal, Licencing, Zurampic, gout, sales
UK drugmaker AstraZeneca (LSE: AZN) on Thursday said it has entered into a licensing agreement worth up to $230 million …
Novartis’ Afinitor gets EU approval to treat cancerous gastrointestinal or lung tumors
June 2, 2016Research and Development, Sales and Marketing Afinitor, Cancer, European Commission, Novartis, regulation
Swiss drugmaker Novartis (VTX: NOVN) on Thursday said the European Commission has approved its Afinitor (everolimus) to treat cancerous gastrointestinal …
Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration
June 2, 2016Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III
Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …
Sanofi looks to set date for showdown with Medivation shareholders
June 2, 2016Sales and Marketing Medivation, Sanofi, hostile, record date, shareholders, takeover
Sanofi (NYSE: SNY) has announced that it has attempted to fix a record date with Medivation (NASDAQ: MDVN) where the …
Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia
June 2, 2016Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia
Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia. Trevicta …
Nice rejects Janssen’s Imbruvica in draft guidance
June 1, 2016Medical Communications, Research and Development
The UK regulators have not recommended Janssen’s leukaemia drug Imbruvica (ibrutinib) to treat in draft guidance. The National Institute for …
Biogen says European regulatory committee adopts positive view for Tysabri
June 1, 2016Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis
Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …
Biomarin withdraws regulatory submissions for Duchenne muscular dystrophy drug
June 1, 2016Research and Development, Sales and Marketing BioMarin, Duchenne Muscular Dystrophy, EMA, FDA, Kyndrisa, failure, rejection
Biomarin (NASDAQ: BMRN) has announced that it has withdrawn its marketing authorisation application for Duchenne muscular dystrophy drug, Kyndrisa (drisapersen), …
GSK’s gene therapy Strimvelis gets European regulatory nod
June 1, 2016Research and Development, Sales and Marketing EU, European Commission, GlaxoSmithKline, Strimvelis, gene therapy, regulation
UK drugmaker GlaxoSmithKline (LSE: GSK) said its gene therapy Strimvelis has secured backing from the European regulators. The European Commission …
FDA approves Lilly/Boehringer Ingelheim type-2 diabetes drug
June 1, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, diabetes, jentadueto, jentadueto xr, lilly, partnership, type 2, type-2
The US Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release) tablets for the …
FDA asks Teva for further study on Huntington drug candidate
June 1, 2016Medical Communications, Research and Development Huntington disease, Teva, US FDA, regulation
Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) said the US regulators have put on hold the approval for its drug to …
AbbVie, Janssen’s Imbruvica gets European approval to teat CLL
May 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, CLL, drug trial, regulation
AbbVie (NYSE: ABBV) on Tuesday said Imbruvica (ibrutinib) has secured European regulatory backing to treat chronic lymphocytic leukemia or CLL. …
Roche launches Bluetooth-enabled self-testing device to check blood clotting in EU
May 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing HealthTech, Heart Conditions, Roche, blood clotting, product launch
Swiss drug firm Roche (Six: ROG) has launched a blood-clott monitoring system for patients with different heart conditions. The CoaguChek …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
